Sofosbuvir/Velpatasvir for Heart Transplant
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial is testing the safety and efficacy of transplanting hearts from HCV seropositive non-viremic and HCV seropositive viremic donors to HCV seronegative recipients. Treatment and prophylaxis will be used to prevent HCV transmission.
Cancer Vaccine
DNA Vaccine for Chronic Hepatitis C
Recruiting1 awardPhase 1
Jacksonville, Florida
This trial studies the side effects and best dose of the DNA vaccine in treating patients with HCV infection. The vaccine may help the body build an effective immune response to kill cancer cells that express HCV infection.
Sodium Hyaluronate for Alcoholic Hepatitis
Recruiting0 awardsPhase < 1
Cleveland, Ohio
This trial involves patients taking a special treatment called HA35 for several months. The goal is to see if HA35 improves health markers like muscle strength and body composition. Participants will undergo various tests to measure these effects.
Cardiac Glycoside
Digoxin for Alcoholic Hepatitis
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial is testing whether a drug called digoxin is effective at treating people with severe alcohol-related liver damage. Patients will be given the drug or a placebo and monitored to see if their liver damage improves.
Popular Filters
Trials for Non-alcoholic Fatty Liver Disease Patients
Semaglutide for Non-alcoholic Steatohepatitis
Recruiting1 awardPhase 3
Madison, Alabama
This trial is studying a medication called semaglutide in patients with NASH. Semaglutide is a well-known medication used to treat type 2 diabetes, and participants will either receive semaglutide or a dummy medication, with no way of knowing which they're getting. The study will last for 5 years, during which participants will have to inject themselves weekly and will have 21 clinic visits and 9 phone calls with clinical staff. Some of the clinic visits may last more than one day.
Efruxifermin for Nonalcoholic Steatohepatitis
Recruiting0 awardsPhase 2
Marrero, Louisiana
This trial is testing a medication called efruxifermin to see if it can help people with a specific liver disease called NASH. The study focuses on patients whose disease has not yet progressed to cirrhosis. The medication works by reducing inflammation and fat in the liver to improve its health.
Trials for NAFLD Patients
Semaglutide for Non-alcoholic Steatohepatitis
Recruiting1 awardPhase 3
Madison, Alabama
This trial is studying a medication called semaglutide in patients with NASH. Semaglutide is a well-known medication used to treat type 2 diabetes, and participants will either receive semaglutide or a dummy medication, with no way of knowing which they're getting. The study will last for 5 years, during which participants will have to inject themselves weekly and will have 21 clinic visits and 9 phone calls with clinical staff. Some of the clinic visits may last more than one day.
Efruxifermin for Nonalcoholic Steatohepatitis
Recruiting0 awardsPhase 2
Marrero, Louisiana
This trial is testing a medication called efruxifermin to see if it can help people with a specific liver disease called NASH. The study focuses on patients whose disease has not yet progressed to cirrhosis. The medication works by reducing inflammation and fat in the liver to improve its health.
Phase 3 Trials
Monoclonal Antibodies
VAY736 for Advanced Cancer
Recruiting0 awardsPhase 2 & 3
Coronado, California
This trial is testing a new medication called VAY736 to help adults with autoimmune hepatitis who haven't responded to or can't tolerate standard treatments. The goal is to see if VAY736 can reduce liver inflammation and improve liver function.
Nucleotide Reverse Transcriptase Inhibitor
Antiviral Therapy for Hepatitis B Transmission Prevention
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial tests antiviral drugs to prevent hepatitis B transmission from mothers to babies. It focuses on high-risk pregnant women and their newborns in Africa. The drugs lower virus levels in mothers and protect babies until they are vaccinated. One of the drugs, Tenofovir disoproxil fumarate (TDF), has been studied for its ability to prevent the spread of hepatitis B from mothers to their babies.
Tyrosine Kinase Inhibitor
Fostamatinib for Autoimmune Hemolytic Anemia
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing the long-term safety of a medication for patients with a condition where their immune system attacks their own red blood cells. The medication works by calming down the immune system to stop this attack. It has shown promising results in treating several autoimmune diseases.
Trials With No Placebo
Anti-viral
Preemptive Mavyret Therapy for Hepatitis C in Organ Transplant Recipients
Recruiting3 awardsPhase 4
Scottsdale, Arizona
This trial is testing if using two medicines together can stop Hepatitis C from spreading to people who get an organ transplant from a donor with Hepatitis C. The goal is to protect the new organ recipient from getting infected by the virus.
Direct Acting Antiviral
Hepatitis C Kidneys Transplantation for Kidney Failure
Recruiting1 awardPhase 2
Miami, Florida
This trial will study whether it is safe to transplant kidneys from donors with hepatitis C into recipients who do not have the virus. One-year allograft function and one-year risk of CMV infection will be compared between THINKER-NEXT kidney transplant recipients and matched recipients who received hepatitis C uninfected kidney transplants. The mortality rate of kidney transplant candidates who enroll in THINKER-NEXT and consent to offers of kidneys from HCV-infected donors will be compared to matched wait-listed patients who do not consent to receive HCV-infected kidneys. Lastly, renal pathologic findings will be compared among HC
Antiviral
Sofosbuvir/Velpatasvir for Kidney Transplant Recipients
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial is testing the safety and efficacy of transplanting kidneys from donors who are either hepatitis C seropositive and non-viremic, or seropositive and viremic, to recipients who are seronegative. Treatment and prophylaxis will be administered using a transmission-triggered approach for the first scenario and a prophylaxis approach for the later scenario.
Direct Acting Antiviral Agent
Epclusa for Chronic Hepatitis C
Recruiting3 awardsPhase 4
Bethesda, Maryland
This trial will study why some people still have liver complications after being cured of hepatitis C. Eligible participants will have different tests and some will take medication for 12 weeks. Then they will have follow-up visits for up to 10 years.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.